Cardiopulmonary Arrest Following a Single 25 mg Dose of Quetiapine: A Case Report
Article Category: Case Report
Pubblicato online: 07 nov 2020
Pagine: 253 - 258
Ricevuto: 30 giu 2020
Accettato: 06 ott 2020
DOI: https://doi.org/10.2478/jccm-2020-0035
Parole chiave
© 2020 Pamela Chia, Lim Chuan Poh, John Ong, Sharon Ong, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Delirium affects up to 80% of patients admitted to intensive care units (ICU) and contributes to increased morbidity and mortality [1, 2, 3]. It is associated with increased ventilator dependence, length of hospital stay, cost of care, long-term cognitive impairment, post discharge institutionalisation and mortality [3]. Pharmacological management include the traditional use of haloperidol, and alternative drugs like dexmedetomidine and quetiapine [1].
Quetiapine is an atypical antipsychotic drug, which has been shown to be effective in the treatment of mental health conditions. It is also widely used in ICUs because of its efficacy in treating ICU delirium [2, 4, 5].
Non-overdose quetiapine induced cardiopulmonary arrest in patients is exceedingly rare. Only two cases in the literature have been reported describing acute respiratory failure after single doses of 50mg and 100 mg [6, 7].
The case is described of an elderly female who developed cardiopulmonary arrest after receiving a single 25 mg dose of quetiapine.
A 72-year-old ethnic Chinese female undergoing haemodialysis, with a history of hypertension, hyperlipidaemia, end stage renal failure (ESRF), transient ischaemic attack, multinodular goitre and gastritis, was diagnosed with a 5.2cm infra-renal abdominal aortic aneurysm. She had no history of obstructive sleep apnoea or respiratory failure. Preoperative physical and airway examination were unremarkable. A transthoracic echocardiogram performed in 2014 showed a left ventricular (LV) ejection fraction of 65%, mild left ventricular hypertrophy and mildly impaired LV diastolic function.
She was admitted to the Singapore General Hospital, a tertiary hospital in Singapore for an elective endovascular aneurysm repair of the infra-renal abdominal aortic aneurysm under general anaesthesia on the day of hospital admission.
Intraoperatively, she required ephedrine (Hameln Pharmaceuticals GmbH, Hameln, Germany) and phenylephrine (Unimedic AB, Matfors, Sweden) which were weaned off at the end of the procedure. Postoperatively she was extubated and transferred to the high dependency unit.
On Day 2 post-admission (post-operative Day 1), she complained of backache during haemodialysis. Subsequently, she became hypotensive (BP 72/34mmHg), bradycardic (heart rate 40 beats/min) and unresponsive, with a Glasgow Coma Scale (GCS) of 3. Dopamine (Hanlim Pharm. Co., Ltd., Gyeong-Gi, Korea) was started at 10mcg/kg/min, which improved her blood pressure and GCS to 11 (E3V2M6). An urgent computed tomography (CT) aortogram was performed to exclude postoperative bleeding from an aortic rupture or the femoral puncture site. The scan reported no evidence of active haemorrhage or blood flow into the aneurysm sac. Immediately after having the CT scan she was transferred to the hospital’s ICU for further management of shock. She was not intubated as she was alert, with a GCS of 15 (E4V5M6). She remained hypotensive but responsive to fluid boluses and blood transfusion. Additionally, her blood pressure was supported with 0.01-0.05mcg/kg/min of noradrenaline (Intega Pte Ltd, Singapore). On Day 2 post-admission to the ICU, a CT scan of the abdomen and pelvis was repeated as there was on-going anaemia, her haemoglobin decreasing from 10g/dL to 7.4g/dL. The scan showed active bleeding from the left common iliac artery and a retroperitoneal haematoma. An emergency x-ray guided stent was inserted via the left common iliac artery on the same day. The patient was intubated electively for the procedure and remained haemodynamically stable throughout.
Upon return to the ICU after the procedure, the patient had blood investigations repeated, a transthoracic echocardiogram and initiation of continuous renal replacement therapy (CRRT). The blood investigations showed markedly elevated liver enzymes and troponin T indicating ischaemic hepatitis and Type 2 myocardial infarction (MI). The transthoracic echocardiogram results indicated a left ventricular ejection fraction as 55% with no regional wall motion abnormality, nor any other abnormalities.
On Day 3, post-admission to the ICU, inotropes, intravenous sedation and analgesia were ceased. She was alert with a recorded GCS score of 11 (E4VTM6) and was extubated immediately after cessation of a fentanyl infusion (Hospira Australia Pty Ltd, Mulgrave, Australia) of 30mcg/hr.
Her arterial blood gas (ABG) post extubation on 3L/min oxygen via nasal prongs was pH 7.3 pCO2 48.6mmHg pO2 157mmHg BE -0.3mmol/L HCO3 23.9mmol/L SaO2 99%. No other sedative medications such as opioids, benzodiazepines, anticholinergics nor antihistamines were administered after extubation.
CRRT was suspended after the circuit filter clotted as there was no indication for continuous dialysis. Eleven hours after extubation, the patient became restless and confused with a GCS of 14 (E4V4M6). She also had a positive score for delirium on the Confusion Assessment Method for ICU and the Richmond Agitation-Sedation Scale.
She did not have a history of dementia, psychiatric illness, epilepsy, or alcohol abuse. On examination, there was no focal neurological deficit and her vital parameters were stable. There were also no infectious foci nor metabolic derangements. Her electrolytes and glucose were within the normal range; glucose 5.5mmol/L, urea 6.1mmol/L, sodium 138mmol/L, potassium 3.8mmol/L, chloride 103mmol/L, bicarbonate 24.5mmol/L, creatinine 161umol/L, magnesium 1.15mmol/L, phosphate 0.95mmol/L, calcium 2.25mmol/L. Anaemia of 8.5g/dL was noted, and she was transfused with a pint of packed red blood cells, although no active source of bleeding had been located.
Twenty-five mg of oral quetiapine (Sandoz Illaç Sanayi ve Ticaret A.Ş., Gebze-Kocaeli, Turkey) was administered, twelve hours after extubation to manage her delirium.
Two hours after quetiapine was administered, the patient was noted to be drowsy and her GCS decreased from 14 to 11 (E3V2M6). A repeat ABG on oxygen of 2L/min showed pH 7.34, pCO2 49mmHg, pO2 82mmHg, BE 0.6mmol/L, HCO3 24.6mmol/L, SaO2 95%. Overnight, apart from tachycardia of 100–108 beats/min, she was otherwise haemodynamically stable. Her oxygen saturation was 92–95% on oxygen of 2L/min and respiratory rate was 17 to 20 breaths/min.
On Day 4 post-admission to ICU at 0610h, seven hours after quetiapine administration, her blood pressure decreased to 74/50mmHg and heart rate to 55 beats/min.
The attending ICU doctor, noted that she was unresponsive with a GCS of 3, and bradypneic with a respiratory rate of less than 12 breaths/min. Her heart rate subsequently slowed to a sinus bradycardia of 40 beats/min and then progressed to pulseless electrical activity within five minutes of the review. Cardiopulmonary resuscitation (CPR) was commenced at 0620h and two intra-venous 1mg boluses of adrenaline (Atlantic Laboratories Corporation Ltd., Samut Prakan, Thailand) were given. She was re-intubated and return of spontaneous circulation was achieved after six minutes of CPR.
An ABG sampled at 0630h immediately after resuscitation, showed primary respiratory acidosis, indicating a Type 2 respiratory failure (pH 6.893, pCO2 168mmHg, pO2 134mmHg, BE -3.9mmol/L, HCO3 19.3mmol/L). The patient was haemodynamically stable post resuscitation and did not require further inotropic support.
The post resuscitation electrocardiogram at 0640h revealed sinus tachycardia with a heart rate of 115 beats/min. The corrected QT interval was not prolonged and there was no elevation of the ST segment.
There was also no expiratory rhonchi on lung auscultation nor witnessed seizures. ABG, renal and liver blood panel were repeated at 0800h. The results showed an improvement of the hypercarbia and acidosis on assist control ventilation (pH 7.5 pCO2 32mmHg pO2 98mmHg BE 2.5mmol/L SaO2 97% HCO3 26mmol/L).
A renal panel investigation revealed no abnormalities (urea 8.3mmol/L, potassium 4.5mmol/L, sodium 143mmol/L, magnesium 1.13mmol/L, phosphate 2.19mmol/L, calcium 2.17mmol/L and glucose 8.6mmol/L) and the result of her liver panel showed a downward trend of her liver enzymes as compared to that on ICU admission (aspartate transaminase 589U/L reduced from 1266U/L, alanine transaminase 313U/L reduced from 614U/L). In addition, post cardiopulmonary arrest, troponin T levels repeated at 0700h, 1200h, and 1800h, also showed a downward trend (troponin T 135 ng/L, 167 ng/L, and 86ng/L). A CT scan of the brain performed soon after resuscitation was reported as normal.
CRRT was recommenced four hours after cardiopulmonary arrest, for fluid removal, as she had a net positive balance of 1.5L in the previous twenty-four hours.
She was extubated uneventfully twenty-four hours after her cardiopulmonary arrest. The next day, Day 5 post-admission to ICU, her GCS was recorded as 15 and she was transferred to the high dependency unit of the hospital.
Despite the abundance of literature on ICU delirium, the evidence for pharmacological treatment is weak and controversial [3,8]. Commonly used medication include typical antipsychotics such as haloperidol, atypical antipsychotics such as olanzapine and quetiapine, or sedatives such as dexmedetomidine [8]. A comparison of drugs used to treat ICU delirium is given in Table 1. However, current evidence does not support a single effective pharmacologic approach for the treatment of ICU delirium [3,8,14].
Drugs used for ICU Delirium
| Haloperidol | Quetiapine | Dexmedetomidine | Olanzapine | |
|---|---|---|---|---|
| Mechanism of action | Nonselective blockade of postsynaptic dopaminergic D2 receptors in the brain [9] | Antagonism of serotonin 5-HT2 and dopamine D2 receptors [9] | Selective α2- adrenergic receptor agonist [9] | Potent antagonist of serotonin 5-HT2A and 5-HT2C, histamine H1, dopamine D1-4, and alpha1-adrenergic receptors. Moderate antagonist of muscarinic M1-5, and 5-HT3 receptors [9] |
| Half life | Decanoate: 21 days Lactate: 20 hours (Intramuscular (IM)) 14-26 hours (IV) 14-37 hours (oral) [9] | 6 hours [10] | Up to 3 hours, significantly prolonged with severe hepatic impairment [9] | Oral and IM: 30 hours; approximately 1.5 times greater in elderly [9] |
| Metabolism | Mainly hepatic metabolism to inactive metabolites [9] | Metabolised by liver to active metabolites with low activity levels [10] | Hepatic metabolism [9] | Mainly hepatic metabolism with 40% removed via first pass metabolism [9] |
| Effect with hepatic impairment | No dosage adjustment needed but concentration may increase in patients with hepatic impairment [9] | Higher plasma levels are expected in the hepatically impaired population, and dosage adjustment may be needed [11] | No dosage adjustment recommended but consider dose reduction in patients with hepatic impairment [9] | No dosage adjustment needed. Use with caution in patients with hepatic impairment [9] |
| Effect with renal impairment | No dosage adjustment needed [9] | Renal insufficiency does not need dosage adjustments. However, in severe renal impairment, alterations in protein binding of quetiapine may affect its pharmacokinetics [10,11] | No dosage adjustment needed [9] | No dosage adjustment needed [9] |
| Peak concentration | Decanoate: 6 days Lactate: 20 minutes (IM) 2-6 hours (oral) [9] | 1-2h [10] | IV loading dose: 15-30 minutes [9] | Short acting injection: 15-45 minutes Extended release injection: ~7 days Oral: ~6 hours [9] |
| Advantages | Low treatment cost [9] | Low risk of EPS (extrapyramidal symptoms) and QTc prolongation compared to typical antipsychotics [1,7] | Analgesia and sedation with minimal respiratory depression [12] | No QTc prolongation [13] |
| Side effects | QTc prolongation, drowsiness, hypotension and EPS [9] | Somnolence, orthostatic hypotension, and tachycardia [9] | Bradycardia, hypotension [9] | Orthostatic hypotension, EPS, weight gain, drowsiness, transaminitis [9] |
Several studies have evaluated the use of quetiapine in ICU, showing its benefit in controlling prolonged delirium with a faster resolution [2,4,5]. In a small randomised control trial of ICU patients with delirium, in addition to “as-needed” haloperidol, patients who were administered quetiapine had a faster resolution of the first episode of delirium, were less agitated and had a greater rate of transfer to home or rehabilitation as compared to a placebo [4]. Another retrospective cohort study evaluating quetiapine therapy for hypoactive delirium in ICU demonstrated a significant decrease in the duration of delirium by twelve hours, compared to patients who received standard care without quetiapine [5]. Nonetheless, data from high quality systematic reviews and meta-analysis are lacking. We are not aware of any reports of cardiopulmonary arrest that is caused by a single dose of 25mg quetiapine in patients without any chronic respiratory condition. A literature search has only shown two case reports of respiratory failure requiring intubation, in patients who did not overdose on quetiapine [6,7]. One had a history of chronic obstructive pulmonary disease (COPD) and was treated for pneumonia, whilst the other was subsequently diagnosed with severe obstructive sleep apnoea syndrome [6,7]. Respiratory depression, requiring intubation and mechanical ventilation, is a known complication of quetiapine overdose, although the reported doses were much higher than those received by our patient [15].
There are several plausible pathways underlying antipsychotic-induced acute respiratory failure that is related to the inhibition of serotonin 5HT2A, dopamine D1 and D2, and histamine H1-receptors. These cause inhibition of the respiratory centre in the brainstem with dystonia and collapse of the upper airway muscles [16].
After excluding all other potential causes, quetiapine is the only reasonable cause of the current patient’s respiratory failure and subsequent cardiopulmonary arrest as she experienced an acute drop of GCS and loss of pulse, seven hours after quetiapine ingestion. Other causes of respiratory failure are unlikely as she did not have a history of neuromuscular disorder or respiratory disease such as obstructive sleep apnoea, COPD or asthma.
There was also no evidence of a new pneumonia as markers of infection (e.g white cell count, C-reactive protein and procalcitonin) were not elevated and a chest radiograph did not show any consolidation. Metabolic factors causing a depressed conscious state were also excluded from her biochemistry results and no other sedatives were administered after extubation. In addition, her conscious level improved rapidly, and she was extubated twenty-four hours following her cardiopulmonary arrest. This also suggests that an acute primary neurological pathology is unlikely since her symptoms were brief and transient. Moreover, a CT scan of her brain was reported as normal. Although the dose of quetiapine administered was small, we hypothesize that the patient’s impaired hepatic function from ischaemic hepatitis, coupled with a reduced renal clearance due to ESRF, led to a transient rise in quetiapine levels which enhanced its effect, leading to respiratory depression and eventual cardiorespiratory arrest.
Dexmedetomidine may be a safer alternative than quetiapine for the treatment of ICU delirium. Table 1 illustrates that it has the best safety profile compared to commonly used drugs. Current recommendations also favour dexmedetomidine for the prevention of ICU delirium and for the treatment of refractory ICU delirium, including ICU patients who are not on mechanical ventilation [3,8]. Further studies are needed to determine its suitability as first line therapy for ICU delirium.
Small doses of quetiapine may cause profound Type 2 respiratory failure and cardiopulmonary arrest, especially in elderly, non-intubated patients with renal and hepatic impairment. Caution is needed when prescribing quetiapine for ICU delirium in such patients.